Ozanimod is used to treat adults with relapsing forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including clinically isolated syndrome. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as anti-inflammatories and multiple sclerosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Zeposia and RPC1063. Its PubChem CID is 52938427.
Ozanimod
| CAS No | 1306760-87-1 |
|---|---|
| Molecular Formula | C23H24N4O3 |
| Molecular Weight | 404.5 g/mol |
| Synonyms | 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ozanimod is used to treat adults with relapsing forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including clinically isolated syndrome.
The listed CAS number is 1306760-87-1.
The listed molecular formula is C23H24N4O3.
The listed molecular weight is 404.5 g/mol.
5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile.
The source lists Zeposia and RPC1063.